VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | The importance of assessing response to CD19 CAR-T therapy in LBCL to confirm disease persistence

Alberto Mussetti, MD, Institut Catala d’Oncologia Hospitalet, Barcelona, Spain, discusses ways in which clinical responses to anti-CD19 CAR-T therapy can be assessed in patients with large B-cell lymphoma (LBCL). Following this, Dr Mussetti explains that biopsies and liquid biopsies may be required to confirm the persistence of disease markers after infusion with CAR-Ts. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter